ASH 2019: Results of a phase III study of acalabrutinib combined with Obinutuzumab in first line treatment of CLL.
Home / Resource Library / ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)